Ramón Castellblanch

    Ramón Castellblanch

    Specialty Drug Prices and the Medi-Cal Program

    Rising specialty drug costs pose a substantial problem for the California state budget and the problem will continue to grow. While these trends are of concern to all payers, this brief focuses on the implications for California’s Medicaid program, Medi-Cal, using the example of Sovaldi, a treatment for hepatitis C.